These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25544836)

  • 1. MYRIAD AFTER
    Conley JM; Cook-Deegan R; Lázaro-Muñoz G
    N C J Law Technol; 2014 Jun; 15(4):597-637. PubMed ID: 25544836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Take off your genes and let the doctor have a look: why the Mayo and Myriad decisions have invalidated method claims for genetic diagnostic testing.
    Bergin C
    Am Univ Law Rev; 2013; 63(1):173-217. PubMed ID: 25335200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene patents and personalized cancer care: impact of the Myriad case on clinical oncology.
    Offit K; Bradbury A; Storm C; Merz JF; Noonan KE; Spence R
    J Clin Oncol; 2013 Jul; 31(21):2743-8. PubMed ID: 23766521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myriad and the mass media: the covering of a gene patent controversy.
    Caulfield T; Bubela T; Murdoch CJ
    Genet Med; 2007 Dec; 9(12):850-5. PubMed ID: 18091435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The History of Patenting Genetic Material.
    Sherkow JS; Greely HT
    Annu Rev Genet; 2015; 49():161-82. PubMed ID: 26442843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do recent US Supreme Court rulings on patenting of genes and genetic diagnostics affect the practice of genetic screening and diagnosis in prenatal and reproductive care?
    Chandrasekharan S; McGuire AL; Van den Veyver IB
    Prenat Diagn; 2014 Oct; 34(10):921-6. PubMed ID: 24989832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The
    Sherkow JS; Cook-Deegan R; Greely HT
    Annu Rev Genomics Hum Genet; 2024 Feb; ():. PubMed ID: 38424474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Opposition to Myriad Genetics patents and their total or partial revocation in Europe: early conclusions].
    Cassier M; Stoppa-Lyonnet D
    Med Sci (Paris); 2005; 21(6-7):658-62. PubMed ID: 15985212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Competition policy in patent cases and antitrust.
    Sobel G
    Adv Genet; 2003; 50():23-64; discussion 507-10. PubMed ID: 14714685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Constructing narratives of heroism and villainy: case study of Myriad's BRACAnalysis(®) compared to Genentech's Herceptin(®).
    Baldwin AL; Cook-Deegan R
    Genome Med; 2013; 5(1):8. PubMed ID: 23369278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Commercial Opportunities and Ethical Pitfalls in Personalized Medicine: A Myriad of Reasons to Revisit the Myriad Genetics Saga.
    So D; Joly Y
    Curr Pharmacogenomics Person Med; 2013 Jun; 11(2):98-109. PubMed ID: 23885284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct to confusion: lessons learned from marketing BRCA testing.
    Matloff E; Caplan A
    Am J Bioeth; 2008 Jun; 8(6):5-8. PubMed ID: 18726769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Impact of Myriad on the Future Development and Commercialization of DNA-Based Therapies and Diagnostics.
    Wales M; Cartier E
    Cold Spring Harb Perspect Med; 2015 Sep; 5(12):. PubMed ID: 26337114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients v. Myriad or the GDPR Access Right v. the EU Database Right.
    Bovenberg JA; Almeida M
    Eur J Hum Genet; 2019 Feb; 27(2):211-215. PubMed ID: 30262921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYRIAD VOICES AGAINST GENE PATENTS IN THE HIGH COURT.
    McCallum L; Faunce T
    J Law Med; 2015 Dec; 23(2):322-9. PubMed ID: 26939499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Supreme Court's spring term: abortion, the right to die, and the decline of privacy rights.
    Wing KR
    J Health Polit Policy Law; 1990; 15(4):919-28. PubMed ID: 2081895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene patents, patenting life and the impact of court rulings on US stem cell patents and research.
    Matthews KR; Cuchiara ML
    Regen Med; 2014 Mar; 9(2):191-200. PubMed ID: 24750060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myriad Genetics: In the eye of the policy storm.
    Gold ER; Carbone J
    Genet Med; 2010 Apr; 12(4 Suppl):S39-70. PubMed ID: 20393310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patenting nature-a comparative perspective.
    Dreyfuss RC; Nielsen J; Nicol D
    J Law Biosci; 2018 Dec; 5(3):550-589. PubMed ID: 31143455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harvard v. Canada: the myc mouse that still squeaks in the maze of biopatent law.
    Deftos LJ
    Acad Med; 2001 Jul; 76(7):684-92. PubMed ID: 11448821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.